Nova Leap Health Corp. Posts Record Q2 2025 Results

Executive Summary

• Nova Leap Health Corp. reported record financial results for the quarter ended June 30, 2025, achieving record consolidated revenues, gross margins, and Adjusted EBITDA.
• The company reported Q2 2025 revenues of $8,021,072, representing a 26.5% increase year-over-year and a 13.1% increase quarter-over-quarter.
• Adjusted EBITDA surged to $577,907, nearly doubling from Q1 2025 and increasing 41.7% compared to Q2 2024, driven by organic expansion and a recent acquisition.

Key Details

• Revenue Performance:
  • Q2 2025 Revenues: $8,021,072.
  • Quarter-over-Quarter Growth: +13.1% (vs. Q1 2025 revenue of $7,093,624).
  • Year-over-Year Growth: +26.5% (vs. Q2 2024 revenue of $6,338,532).
• Profitability Metrics:
  • Adjusted EBITDA: $577,907 (Q2 2025), up 99.9% from Q1 2025 ($289,060) and 41.7% from Q2 2024 ($407,896).
  • Gross Profit Margin: 40.2% in Q2 2025, compared to 39.0% in Q1 2025 and 38.4% in Q2 2024.
  • Adjusted EBITDA Margin: Expanded to 7.2% in Q2 2025, up from 4.1% in Q1.
  • Income from Operating Activities: $350,439 in Q2 2025, an increase of $275,287 from Q1 2025 and $102,730 from Q2 2024.
  • Net Income/Loss: Net loss of $484,008 in Q2 2025 (compared to net loss of $78,299 in Q1 2025 and net income of $226,998 in Q2 2024).
• Balance Sheet & Liquidity:
  • Available Cash: $1,393,284 as of June 30, 2025.
  • Credit Facility: Full access to unutilized revolving credit facility of $1,099,465 (CAD$1,500,000).
  • Total Credit Access: Up to $4,691,000 available through existing credit agreements.
  • Debt: Total demand loans and promissory notes outstanding were $2,434,682 as of June 30, 2025.
  • Leverage Ratio: 1.47 times to Adjusted EBITDA of $1,659,030 for the 12-month period ending June 30, 2025.
• M&A Activity:
  • On May 5, 2025, the Company acquired a home care business in Nova Scotia.
  • Consideration: CAD$390,000, paid in cash on closing.
  • Financing: Financed with cash on hand.
• Operational Highlights:
  • Record performance achieved across Canadian and U.S. operating segments, including revenues, gross margins, and Adjusted EBITDA.
  • Insider ownership rose to 42.26% as directors and officers increased their holdings.

Notable Quotes

• “In May, I said we expected a record Q2. We delivered exactly that—and more,” said Chris Dobbin, President & CEO. “Q2 2025 was the strongest quarter in Nova Leap’s history, setting records across every major metric: revenue, gross margin, and Adjusted EBITDA.”
• “These results were driven by both organic expansion and our recent acquisition in Nova Scotia. Operating leverage is becoming evident—Adjusted EBITDA margin expanded to 7.2%, up from 4.1% in Q1—as scale and discipline translate into better returns.”